Travere Therapeutics, Inc.

NASDAQ:TVTX

Biotechnology

Healthcare
$50.24 +1.20%

+$0.65 today

Market cap
$4.82B
Beta
1.14
P/E (TTM)
-235.0
EPS (TTM)
-$0.23
52W Low $13.97High $55.99

Volume 0.84M

Average 2.31M

TVTX Pre-Tax Margin

Income before tax as a percentage of revenue.

Travere Therapeutics, Inc.NASDAQ: TVTX

Pre-Tax Margin · Q3 FY2026 · quarter ended Sep 2026

Pre-tax margin narrows to -29.8%

Pre-tax margin was -29.8% in Q3 FY2026, down 45.4 pp from a year earlier. On a trailing-twelve-month basis it was -24.5%, down 4.2 pp year over year. Over 3 fiscal years it widened by 292.5 pp.

Context

  • Pre-tax margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
-29.8%-9.2 pp QoQ
Last fiscal yearDec 2025
-10.0%+127.4 pp YoY
LTMSep 2026
-24.5%-4.2 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-45.4 pp——
1 year+127.4 pp——
3 years+292.5 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-10.0%
Year-over-year change
+127.4pp

Pre-Tax Margin vs competitors

How TVTX compares with its peers on the latest reported figures

  • TVTX's LTM Sep 2026 pre-tax margin of -24.5% is the 2nd highest of the 4 companies compared; the peer median is -612.7%.
  • Its year-over-year change of -4.2 pp is the 3rd highest of 4, against a peer median of +6.5 pp.
  • Over three fiscal years its change of +292.5 pp compares with a peer median of -3.9 pp.
TVTX Competitors Peer median
Pre-Tax Margin for TVTX and competitors
Company Period LTM level YoY 3-year change
PHARPharming Group N.V.LTM Mar 20265.4% +6.5 pp-3.9 pp
TVTXTravere Therapeutics, Inc.LTM Sep 2026-24.5% -4.2 pp+292.5 pp
MAZEMaze Therapeutics, Inc.LTM Mar 2026-612.7% -644.4 pp—
PROKProKidney Corp.LTM Mar 2026-17599.3% +36668.3 pp—
MLYSMineralys Therapeutics, Inc.FY2025— ——
Peer median (excluding TVTX) -612.7%+6.5 pp-3.9 pp

Competitors are the stored peer set for TVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue131.84M109.46M145.24M233.18M490.73M
Cost of Revenue3.82M4.42M11.45M7.74M10.34M
Gross Profit128.02M105.04M133.79M225.43M480.39M
Gross Margin97.1%96.0%92.1%96.7%97.9%
Research & Development201.16M227.33M244.99M282.7M206.01M
Selling, General & Admin126.28M197.52M265.54M264.12M337.2M
Operating Expenses327.44M424.85M521.93M549.26M543.21M
Depreciation & Amortization12.75M20.72M38.53M43.56M60.74M
EBITDA(184.46M)(299.42M)(326.25M)(265.77M)22.22M
EBITDA Margin-139.9%-273.5%-224.6%-114.0%4.5%
Operating Income(199.43M)(319.81M)(388.14M)(323.83M)(62.82M)
Operating Margin-151.3%-292.2%-267.2%-138.9%-12.8%
Interest Income1.99M6.28M21.77M17.82M12.72M
Interest Expense19.68M11.01M11.33M11.18M10.75M
Other Income / Expenses(17.46M)(11.34M)12.03M3.32M13.55M
Income Before Tax(216.88M)(331.16M)(376.11M)(320.51M)(49.27M)
Pre-Tax Margin-164.5%-302.5%-259.0%-137.5%-10.0%
Income Tax Expense409K313K223K120K988K
Net Income(180.09M)(278.48M)(111.4M)(321.55M)(25.55M)
Net Margin-136.6%-254.4%-76.7%-137.9%-5.2%
EPS (Basic)(3.01)(4.37)(1.50)(4.08)(0.56)
EPS (Diluted)(3.01)(4.37)(1.50)(4.08)(0.56)
Weighted Avg Shares59.83M63.76M74.27M78.89M89.21M
Weighted Avg Shares (Diluted)59.83M63.76M74.27M78.89M89.21M

Travere Therapeutics, Inc.

NASDAQ:TVTX

Intrinsic Alpha fair value

Locked

Current Price

$50.24

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.